Business Description
Neuraxis Inc
NAICS : 541714
SIC : 2834
ISIN : US64134X2018
Total Employee Number:
24Description
Neuraxis Inc is a growth-stage medical technology company focused on neuromodulation therapies for chronic and debilitating conditions in the gastrointestinal (GI) digestive system, specifically from disorders of the gut-brain interaction (DGBIs) in pediatrics and adults. The company is dedicated to advancing the science with its' proprietary Percutaneous Electrical Nerve Field Stimulation (PENFS) technology. The company focuses on targeted therapies for the pediatric and adolescent population suffering from disorders of gut-brain interaction (DGBIs).
Financial Strength
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 20 | |||||
Equity-to-Asset | 0.66 | |||||
Debt-to-Equity | 0.06 | |||||
Debt-to-EBITDA | -0.05 | |||||
Piotroski F-Score | 4/9 | |||||
Altman Z-Score | 4.94 | |||||
Beneish M-Score | -2.59 | |||||
WACC vs ROIC | ||||||
Growth Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 7.2 | |||||
3-Year EBITDA Growth Rate | -18 | |||||
3-Year EPS without NRI Growth Rate | -9.4 | |||||
3-Year FCF Growth Rate | -37.2 | |||||
Future 3-5Y Total Revenue Growth Rate Estimate | 109.74 |
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 31.9 | |||||
9-Day RSI | 41.26 | |||||
14-Day RSI | 44.39 | |||||
3-1 Month Momentum % | -4.15 | |||||
6-1 Month Momentum % | 36.18 | |||||
12-1 Month Momentum % | 179.17 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 2.89 | |||||
Quick Ratio | 2.81 | |||||
Cash Ratio | 2.52 | |||||
Days Inventory | 87.9 | |||||
Days Sales Outstanding | 18.13 | |||||
Days Payable | 264.94 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -20.8 | |||||
Shareholder Yield % | -7.97 |
Profitability Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 85 | |||||
Operating Margin % | -169.96 | |||||
Net Margin % | -170.12 | |||||
EBITDA Margin % | -166.22 | |||||
FCF Margin % | -144.17 | |||||
OCF Margin % | -141.53 | |||||
ROE % | -228.41 | |||||
ROA % | -117.3 | |||||
ROIC % | -341.02 | |||||
3-Year ROIIC % | 143.25 | |||||
ROC (Joel Greenblatt) % | -2057.56 | |||||
ROCE % | -201.34 | |||||
Moat Score | 2 | |||||
Tariff Resilience Score | 6 |
GF Value Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PS Ratio | 16.82 | |||||
PB Ratio | 14.3 | |||||
Price-to-Tangible-Book | 14.9 | |||||
EV-to-EBIT | -11.39 | |||||
EV-to-EBITDA | -11.5 | |||||
EV-to-Revenue | 19.11 | |||||
EV-to-FCF | -13.26 | |||||
Price-to-GF-Value | 2.44 | |||||
| Price-to-Net-Current-Asset-Value | 15.89 | |||||
| Price-to-Net-Cash | 19.86 | |||||
Earnings Yield (Greenblatt) % | -8.78 | |||||
FCF Yield % | -6.97 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with AMEX:NRXS
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Neuraxis Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 4.281 | ||
| EPS (TTM) ($) | -0.81 | ||
| Beta | - | ||
| 3-Year Sharpe Ratio | - | ||
| 3-Year Sortino Ratio | - | ||
| Volatility % | 77.1 | ||
| 14-Day RSI | 44.39 | ||
| 14-Day ATR ($) | 0.392811 | ||
| 20-Day SMA ($) | 7.02 | ||
| 12-1 Month Momentum % | 179.17 | ||
| 52-Week Range ($) | 2.1963 - 9.33 | ||
| Shares Outstanding (Mil) | 12.38 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 4 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Neuraxis Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Neuraxis Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| Third quarter earnings conference call for 2026 | 2026-11-30 | In 139 days | ||
| Third quarter earnings results for 2026 | 2026-11-30 | In 139 days | ||
| Second quarter earnings conference call for 2026 | 2026-08-31 | In 48 days | ||
| Second quarter earnings results for 2026 | 2026-08-31 | In 48 days | ||
| General meeting for 2026 | 2026-06-10 09:00 | 6.80 (+1.95%) | ||
| First quarter earnings conference call for 2026 | 2026-05-12 09:00 | 8.15 (-2.86%) | ||
| First quarter earnings results for 2026 | 2026-05-12 | 8.15 (-2.86%) | ||
| Fourth quarter earnings conference call for 2025 | 2026-03-19 09:00 | 6.99 (-5.03%) | ||
| Annual report for 2025 | 2026-03-19 | 6.99 (-5.03%) | ||
| Fourth quarter earnings results for 2025 | 2026-03-19 | 6.99 (-5.03%) |
Show
Entries
Neuraxis Inc Frequently Asked Questions
What is Neuraxis Inc(NRXS)'s stock price today?
The current price of NRXS is $7.15. The 52 week high of NRXS is $9.33 and 52 week low is $2.20.
When is next earnings date of Neuraxis Inc(NRXS)?
The next earnings date of Neuraxis Inc(NRXS) is 2026-08-31 Est..
Does Neuraxis Inc(NRXS) pay dividends? If so, how much?
Neuraxis Inc(NRXS) does not pay dividend.
Guru Commentaries on AMEX:NRXS
No articles.
Press Release
Articles on Neuraxis Inc
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers